SCOPING REVIEW 1
SCOPING REVIEW: DETERMINANTS OF DISEASE IN INFLAMMATORY BOWEL
DISEASES BETWEEN THE DEVELOPING COUNTRIES AND THE WESTERN WORLD
Name
Class
Professor
Institution
City and State
Date
SCOPING REVIEW 2
Table of Contents
Abstract............................................................................................................................................3
SCOPING REVIEW: DETERMINANTS OF DISEASE IN INFLAMMATORY BOWEL
DISEASES BETWEEN THE DEVELOPING COUNTRIES AND THE WESTERN WORLD...5
Introduction, Aims, and Objectives..................................................................................................5
Methodology....................................................................................................................................8
Design:........................................................................................................................................8
Underpinning Research Question:.........................................................................................10
Identifying Relevant Studies:..................................................................................................11
Study Selection:........................................................................................................................11
Inclusion & Exclusion Criteria:.............................................................................................12
Charting the Data:...................................................................................................................13
Collating and Reporting:........................................................................................................15
Main Body......................................................................................................................................16
Discussion and Conclusion............................................................................................................42
Strengths and Limitations:.....................................................................................................45
Recommendations for Future Research:...............................................................................46
Implications for Practice:........................................................................................................47
Conclusion.....................................................................................................................................47
References List..............................................................................................................................49
SCOPING REVIEW 4
Abstract
Background: Inflammatory bowel disease (IBD) patients face significant problems such as
medical, psychological, social, and economic challenges. This scoping review compiles the
current literature to address gaps in the knowledge and identify new research possibilities. Some
of the most significant issues examined include new treatment choices, financial burdens, mental
health effects, and medical problems linked to inflammatory bowel disease (IBD). The study
reveals the importance of developing unique treatment plans for each patient, which highlights
the disease’s complexity.
Methods: Journals and articles about inflammatory bowel disease (IBD) were searched in
electronic sources like Web of Science, Embase, PubMed, and Embase. We used MeSH terms
and keywords related to inflammatory bowel disease (IBD), its prevalence, causes, and
appropriate treatment methods. Only studies that met specific criteria were considered for data
extraction and synthesis.
Results: The study discusses how biologic medicines and small compounds have become more
popular recently as possible ways to treat inflammatory bowel disease. It further highlights
problems like patients' lack of willingness to pay for care and other issues. Managing illnesses
and addressing treatment effects are challenging without dealing with differences in healthcare
access, cultural norms, and socioeconomic status. The scoping review reveals that people with
inflammatory bowel disease (IBD) suffer in their workplaces. The disease makes them miss
work, spend a lot of money on medical bills, and lower their quality of life. Thus, developing
treatments that ease symptoms and financial concerns is essential. The research emphasizes the
significance of using treatments from different fields and gives each patient-centered,
individualized care.
SCOPING REVIEW 5
Conclusion: Irritable bowel disease (IBD) is a massive problem for healthcare systems around
the world. To address it, personalized treatment plans and more studies are needed. Personalized
drugs and multidisciplinary care are essential to help patients improve and have a better quality
of life. Healthcare stakeholders should invest in research to deal with the complicated issues of
inflammatory bowel disease (IBD) and improve patient care better.
Keywords: Inflammatory bowel disease (IBD), Global burden, epidemiology, regional
disparities, genetic disposition, environmental factors, lifestyle factors, psychosocial factors,
healthcare disparities, treatment modalities, economic burden, quality of life
SCOPING REVIEW 6
SCOPING REVIEW: DETERMINANTS OF DISEASE IN INFLAMMATORY BOWEL
DISEASES BETWEEN THE DEVELOPING COUNTRIES AND THE WESTERN WORLD
Introduction, Aims, and Objectives
Some genetic, environmental, and social factors can lead to inflammatory bowel disease
(IBD). These factors also impact IBD’s development and prevalence (Rajbhandari et al., 2020;
Greuter et al., 2020). In developed countries, these factors have been widely studied. However,
there have been minimal studies in developing countries. Inflammatory bowel disease (IBD)
prevalence rates vary in different parts of the world (Rajbhandari et al., 2020). That is partly
because problems, such as other environmental risks, genetic predispositions, and limited access
to healthcare resources, differ from one place to another. Most people with IBD get it from their
family (Truta et al., 2023). Many genetic differences increase a person’s susceptibility to the
disease. Many genetic studies in the West have found different risk factors for inflammatory
bowel disease (IBD). However, few studies have been done on the genetics of inflammatory
bowel disease (IBD) in developing countries. Some groups may be more likely to get
inflammatory bowel disease (IBD) because of differences in their DNA (Truta et al., 2023).
These variances may also change how likely someone is to get IBD and how quickly it gets
worse. Knowing about these physical differences is essential so that different groups can get
treatment plans and other help that fits their needs.
A significant correlation exists between the environment and inflammatory bowel disease
(IBD), but these links are less intense in developing countries than they are in developed ones.
People in the West get IBD from the foods they eat, the cigarettes they smoke, and poor hygiene
(Salgado et al., 2020). On the other hand, people in poor countries can be exposed to the
SCOPING REVIEW 7
environment differently depending on how clean the area is, the number of common diseases
present, and what people eat (Salgado et al., 2020). Living in a poor country increases the risk of
developing inflammatory bowel disease (IBD) because one is likelier to get parasites and
common intestinal diseases. In some developing areas, people are quickly moving to cities and
adopting Western ways of life (Salgado et al., 2020). That complicates the link between climate
and disease risk because it could change what people eat and how they interact with the world.
Inflammatory bowel disease (IBD) costs more in poor countries than in rich ones due to
limited access to health care. According to Park and Cheon (2021), Western countries have better
healthcare systems, so people with inflammatory bowel disease (IBD) can get a faster diagnosis
and the expert care they need. Consequently, they can better handle their illness and get better
results. It can be challenging to have inflammatory bowel disease (IBD) in developing countries
due to insufficient hospitals, drugs, or diagnostic tools (Park and Cheon, 2021). Failure to pay for
preventative care and adhering to treatment plans worsens the condition and increases its
mortality rates.
The rates and symptoms of inflammatory bowel disease (IBD) are very different from
one place to another. Glassner et al. (2020) noted that genetic, environmental, and social factors
interact in complicated ways. During the last few decades, children in wealthy countries like the
US and EU have been getting inflammatory bowel disease (IBD) more often. An exciting
combination of genetics, society, and better diagnosis tools can explain the current trend. It is
hard to study the number of people with inflammatory bowel disease (IBD) in many poor
countries because not enough is known about the disease’s prevalence and commonality
(Glassner et al., 2020). However, new information shows that these places are recording a rise in
SCOPING REVIEW 8
inflammatory bowel disease (IBD). Epidemiology has also changed because people are moving
to cities and changing what they eat and how they live.
Rich and developing countries should work together to close the gaps in research and
health care, provide more information about inflammatory bowel disease (IBD), and provide
better care to people globally. Researchers, doctors, and politicians of different races should
collaborate to fill in the gaps in knowledge and funds (Cury et al., 2019). As part of this, they
should review epidemiology to determine IBD’s popularity in various places. We also need to
look into how genetic and environmental factors affect the disease in other groups of people.
Finally, we need to find ways to make it easier for people who live in low-income places and
have inflammatory bowel disease to get medical care. Regardless of where they live or how
much money they have, people with irritable bowel disease (IBD) should get high-quality care.
By eliminating these hindrances, we can lower the number of people who get this sickness
worldwide.
The main point of this study is to explore the differences between the causes of
inflammatory bowel disease (IBD) in Western and developing countries. By combining the
newest study with care, we hope to give a comprehensive view of the factors that affect
inflammatory bowel disease’s (IBD) prevalence in different social and cultural settings. This
study compares inflammatory bowel disease (IBD) manifests in various places to learn more
about how genetic, environmental, and social factors affect each other. That entails examining
similarities and differences in these factors. These traits should help us determine how to best
help IBD patients in poor countries. The main goal of this scoping study is to close the
knowledge gap between developed and developing areas to develop ways to lessen the effects of
inflammatory bowel disease (IBD) worldwide.
SCOPING REVIEW 9
This study will also examine the complicated differences between countries that are close
to each other. Understanding the complex factors affecting inflammatory bowel disease (IBD)
growth is essential. Regarding inflammatory bowel disease (IBD), access to healthcare, food,
cleanliness, and the number of people living in cities can worsen the disease for some groups of
people. Even in a developing country, these differences can be significant. We can learn more
about the local factors that affect the number of cases and symptoms of inflammatory bowel
disease (IBD) by examining these changes within areas. In poor countries, this shows the
importance of investigating each case in great detail to ensure that everyone with inflammatory
bowel disease (IBD) gets fair care and better results.
Additionally, this study seeks to close the knowledge gap between developing and
developed countries. It emphasizes the significance of personalized therapies for dealing with the
different types of Inflammatory Bowel Disease (IBD) that happen in other areas. This in-depth
study will help researchers, healthcare workers, and policymakers develop better ways to deal
with and stop inflammatory bowel disease (IBD) in various social and cultural settings. Since
inflammatory bowel disease (IBD) can occur in diverse places and different people, personalized
methods improve treatment and help patients recover fully. People with inflammatory bowel
disease (IBD) could be helped more by creating treatments that are specific to their needs and
issues. Regardless of where a person lives or their financial status, our study shows that
personalized measures can help people with inflammatory bowel disease (IBD) address their
condition and have better health results.
Methodology
Design: This scoping study was based on Arksey and O'Malley’s model; this research method
carefully and thoroughly examines challenging study topics. Based on looking into the illness's
SCOPING REVIEW 10
causes and possible treatments, this framework helps one understand the large body of studies
exploring inflammatory bowel disease (IBD). To shed light on inflammatory bowel disease
(IBD), the study examines several factors, including genetic predispositions, differences in
socioeconomic status, environmental factors, and the ease of access to medical care. A thorough
analysis is the primary goal of this study, which aims to shed light on the complicated links
between different socioeconomic situations and the start of inflammatory bowel disease (IBD).
Thus, we can see how the sickness and its treatment affect different groups of people and places.
The review uses Arksey and O'Malley’s model to find knowledge gaps in inflammatory bowel
disease, making it possible for policies and treatments based on data to help lower the number of
cases worldwide.
The study will review different factors to outline how the causes of inflammatory bowel
disease (IBD) differ in rich and poor countries. Our comprehensive approach will detail the
complicated factors affecting how inflammatory bowel disease (IBD) is treated and worsens. In
developing countries, inflammatory bowel disease (IBD) is different from Western countries
because of variations in genetics, environment, socioeconomic standing, and access to care. This
review aims to find studies that have examined these differences and compile them. Healthcare
professionals need a deep knowledge of these factors to ensure treatments and strategies are
tailored to each region's specific problems and needs.
Much research has been done on how DNA susceptibility genes differ between people
from the West and other parts of the world. That supports the idea that inflammatory bowel
disease (IBD) is a hereditary condition. Our goal is to review the newest studies for any proof
that genetic markers affect how diseases are passed on or show up differently in some groups of
people. Individuals with inflammatory bowel disease (IBD) are often more careful about what
SCOPING REVIEW 11
they eat, their hygiene, and their surroundings. By doing this study, we want to learn more about
how phenotypes show up in places with few resources and the impact of external factors on the
risk of getting sick in the West.
IBD is more prevalent in low-income countries, with poor schooling and limited access to
health care. These are examples of social determinants. This study will utilize differences in
social status to show how hard it is for poor countries to get early diagnoses, comprehensive
treatment plans, and manage diseases well. The findings will help authorities know where to
send aid and make policy choices based on accurate information. Living in developing countries
makes it harder for people with inflammatory bowel disease (IBD) to get treatment because of
differences in healthcare facilities, medication availability, and cost. We aim to improve
healthcare quality and outcomes for low-income areas by finding research gaps and developing
ways to address them.
Underpinning Research Question: Following the SPIDER framework, this study examines the
complicated factors that affect the number of people with inflammatory bowel disease (IBD) and
how they are treated across various population groups. The current study used a planned
approach to examine how the SPIDER structure's different parts (Sample, Phenomenon of
Interest, Design, Evaluation, and Research Type) interact. The project aims to better understand
IBD and its signs by assessing the many IBD-affected samples from various social and economic
backgrounds. The review focuses on the symptoms and signs of IBD and the more significant
social and environmental factors that affect how the sickness starts and progresses. The study's
goal is to carefully evaluate the body of literature by using strict research designs and evaluation
methods. It combines data to find trends, patterns, and differences in IBD’s prevalence and
treatment approaches. We will use a multimodal study method combining quantitative and
SCOPING REVIEW 12
qualitative methods to understand the complicated dynamics that cause IBD entirely. That will
make it more likely that personalized solutions and policy suggestions can be made to help many
different groups of people.
Identifying Relevant Studies: A thorough search plan was carefully made using relevant
keywords and Medical Subject Headings (MeSH) terms to ensure all the literature was reviewed.
These words were chosen because they reveal how much study has been done on inflammatory
bowel disease (IBD) in developed and developing countries. We evaluated several academic
databases, like Web of Science, PubMed, and Scopus, to find essential studies that met our
needs. We considered several factors to ensure that only studies that add much to what we
already know about the causes of inflammatory bowel disease (IBD) in those cases were chosen.
To find out how the study of inflammatory bowel disease (IBD) changed, we only looked at
papers from 1990 to 2023. We will get the most up-to-date and valuable proof if we work on this
time frame.
Study Selection: The PRISMA extension for scoping reviews (PRISMA-ScR) checklist was the
primary tool for this scoping review. It ensured that the research summary was consistent and
open. That helped the review keep the screening process organized and consistent, ensuring that
each step was done correctly and in a way that was easy to understand. The thorough instructions
on the checklist included finding relevant research, assessing search results, and choosing good
papers for the review. The review's results were more accurate and reliable because of this strict
process, which made decision-making more consistent and less likely to be biased. Finally, the
study followed the required steps for methods by using the PRISMA-ScR checklist.
Consequently, studies on inflammatory bowel disease (IBD) and its causes and treatment were
likely reliable. The PRISMA-ScR checklist during screening showed that the study was
SCOPING REVIEW 13
dedicated to scientific integrity and openness. Ultimately, this checklist made the findings more
valid and reliable. A table of the accepted studies is in the appendix.
We carefully chose and reviewed papers that followed these strict rules to learn more
about the causes of inflammatory bowel disease (IBD) and possible treatments for people in
developing and developed countries with this long-term inflammatory disorder. Screening and
choosing were the first two steps in the planned review. The following steps were to get the data
and make a graph. A structured study into what causes inflammatory bowel disease (IBD) led to
the creating of a data-gathering form. Much work was focused on making this form to ensure the
extraction process was complete and consistent. The method for extracting data from each study
got valuable data. This group included everything from the study's methods to the community's
people, location, and traits that were looked at. Much research was also done on how genetics,
society, the surroundings, and the ease of access to therapies affect the development and
treatment of inflammatory bowel disease (IBD).
Inclusion & Exclusion Criteria: Researchers from developed and developing countries
reviewed what makes people more likely to get inflammatory bowel disease (IBD). We can use
this organized way to examine how the social and economic factors that affect other countries'
healthcare systems impact the spread and management of diseases. Assessing the differences and
similarities between the numbers from these two regions is helpful to learn more about
inflammatory bowel disease (IBD) worldwide. We omitted some things to ensure the review was
still beneficial and of good quality. That comprised all the study papers that were not written in
English. To keep the integrity of the analysis, we eliminated publications that did not meet our
inclusion standards, such as those exploring diseases or treatments that had nothing to do with
our goals.
SCOPING REVIEW 14
Setting clear criteria for inclusion as part of this review is essential for ensuring the
science is sound and picking valuable studies. A vital part of these standards is ensuring that
materials are written in English so that many people can read and understand them. The studies
must also directly affect our understanding of the factors that change how inflammatory bowel
disease (IBD) is treated and its prevalence in different socioeconomic settings. The quality
criteria also helped us choose research that follows strict scientific procedures and gave us high-
quality data on the subject being studied. The review aims to fully explain these factors for
inclusion so that the selection process stays open, fair, and excellent. Consequently, the results
will be reliable and accurate.
Charting the Data: The data was organized logically so that charts could be used to make it
easy to examine and understand. Each data point was carefully charted according to the
categories already set up in the data extraction form (Appendix 1). That made it easy to find
trends and compare experiments. Thematic analysis was used to combine the collected data.
Carefully examining the information revealed patterns and themes about what causes
inflammatory bowel disease (IBD). That highlighted many things that can cause or worsen the
condition and change how it is treated. Genetic, environmental, social, and treatment access
factors affect how inflammatory bowel disease (IBD) occurs. More regional differences and
repeating trends in this area could be found using thematic analysis. Through this synthesis
method, we fully understood the many causes of inflammatory bowel disease (IBD). It also laid
the ground for evidence-based policy and intervention ideas that can be changed to fit the needs
and problems of different groups.
This in-depth review that carefully collects and puts together data will provide crucial
lessons about inflammatory bowel disease’s causes. The goal is to improve the health and quality
SCOPING REVIEW 15
of life of people with IBD worldwide. Risk factors for inflammatory bowel disease (IBD) differ
in poor countries. Each type of analysis was used with others to provide comprehensive insight
into the subject. Subgroups were made based on factors unique to each place, such as the food
people eat, their cultural practices, and the health care services they access. We split the data into
groups to identify slight differences in how inflammatory bowel disease (IBD) is handled and its
prevalence in different places. Such findings are essential for creating answers that work best for
certain groups of people.
We also reviewed the risks of the results to determine their stability and how any biases
might have changed the general outcomes. To do these sensitivity studies, we carefully tried
different ways to include the studies, such as changing the release date range or looking at
different study designs. We did this while closely examining how each change affected the
review results. These analyses helped to add more weight to what we found by ensuring that our
results, conclusions, and ideas were valid and solid. We carefully examined the groups included
to see where the data might have been wrong. That gave us a more detailed picture of the factors
that cause inflammatory bowel disease (IBD) in developing countries and developed
communities. In the end, these sensitivity analyses strengthened our study's results.
Relevant stakeholders were also involved in the review to ensure the findings were
helpful and could be used in the real world. They included healthcare workers, lawmakers, and
patient support groups; they helped make the protocol and determine the results. We asked many
different groups what they thought to find valuable things about how the data might change
clinical practice, patient advocacy, and public health policy. Getting together to discuss
inflammatory bowel disease (IBD) and find suitable solutions to its problems shed new light on
their complexity. Including the stakeholders’ views in our review made the results more valuable
SCOPING REVIEW 16
and reliable. It also encouraged people to work together to control and stop IBD by making
choices and sharing information. This approach of engaging stakeholders ensured that the results
were valid, meaningful, and doable so that the scoping review could have the most positive effect
on creating healthcare policies and services.
Collating and Reporting: The data for this study were compiled using thematic analysis,
making it easier to identify recurrent themes and trends regarding the origins and management of
inflammatory bowel disease (IBD) among individuals of various locations and ages. This
approach guided the analysis of the gathered data, providing us with hints about the interplay of
genetic predisposition, socioeconomic status, and unequal access to healthcare that impact the
onset and course of IBD. By examining broad concepts in various settings and populations, the
research obtained a comprehensive understanding of the complexity of IBD and its management.
These broad concepts comprised societal and economic barriers, environmental variables, and
genetic predispositions.
Sensitivity tests were also conducted to assess the robustness and reliability of the study
results and ensure that they were solid and would not be affected by inconsequential
methodological errors or adjustments to the study's setup. Researchers gained confidence in the
study's correctness and increased the validity and trustworthiness of its results due to this
rigorous validation approach. Involving stakeholders was crucial to ensuring the study's findings
were applicable and meaningful. Policymakers, patient advocacy organizations, and medical
professionals reviewed the findings. This validated the study's conclusions and facilitated their
translation into workable strategies and evidence-based treatments that will enhance the health of
IBD patients everywhere. Stakeholder involvement, sensitivity analyses, and thematic analysis
are the main components of this process. It offers a thorough and reliable foundation for
SCOPING REVIEW 17
comprehending and addressing the intricate problems that IBD raises. Ultimately, it enables
decision-makers and other relevant stakeholders to make better choices regarding supporting the
health and welfare of impacted individuals worldwide.
Main Body
After doing a scoping review, thirty papers were found to be helpful. The topics of these
papers were comprehensive and dealt with the causes, risk factors, and rates of inflammatory
bowel disease (IBD) in different places of the world. Many things were assessed in these studies,
like how inflammatory bowel disease (IBD) affects people worldwide, its prevalence in various
areas, genetic and environmental risk factors, changes in healthcare, delays in diagnosis, and
other IBD treatment methods. Several types of data were used in the study to show how genetics,
socioeconomic class, access to health care, and genetics all affect each other in complicated
ways. The findings revealed that inflammatory bowel disease (IBD) has many aspects.
To highlight the complicated problems people with Inflammatory Bowel Disease (IBD)
face, the scoping review carefully examines all the different challenges associated with the
disease. That involves compiling information from various scholarly sources. Mak et al. (2020)
and Fróes et al. (2024) show the risks of complications like strictures, fistulas, abscesses, and
signs outside the intestines like arthritis and skin problems. Abegunde et al. (2016) discuss the
critical effects of strictures, focusing on how they can block the intestines, leading to unpleasant
symptoms like stomach pain and changes in bowel habits. The findings give a complete picture
of the many problems that can happen with IBD by including the results of these critical studies
and emphasizing how these complications significantly affect the patient's quality of life and
medical care Mak et al., 2020; Fróes et al. 2024; Abegunde et al., 2016). This in-depth study
highlights the essence of using customized approaches to deal with the tricky issues arising from
SCOPING REVIEW 18
IBD complications (Fróes et al., 2024). The goal is to improve patient care and outcomes in this
complex clinical setting.
Epidemiological Trends: Inflammatory bowel diseases (IBD) like Crohn's disease (CD) and
ulcerative colitis (UC) affect people with rich and poor economies. It is a significant and growing
health problem around the world. Epidemiologists like Molodecky et al. (2012) and Alatab et al.
(2020) have found that inflammatory bowel disease (IBD) has grown significantly in the last few
decades. Studies indicate different racial and ethnic groups are getting inflammatory bowel
disease (IBD). It has become a bigger problem for public health (M'Koma, 2013). The global
increase in inflammatory bowel disease means it is becoming more common. These changes are
due to changes in genes, lifestyles, and the surroundings. IBD, or inflammatory bowel disease, is
getting worse and worse for patients and healthcare systems all over the world (Molodecky et al.,
2012). This trend shows the importance of better control, faster diagnosis, and better monitoring.
It has always been more common in developed Western countries, but inflammatory
bowel disease (IBD) is becoming more common in low-income nations too. Kaplan and Ng
(2017) and Glassner et al. (2020) have helped explain why this occurs. The way diseases spread
in the poor world has changed in a new and more scary way. Park and Cheon (2021) discovered
that inflammatory bowel disease (IBD) is becoming more common and happens more often in
Asia. Hodges and Kelly (2020) and Saracino et al. (2023) state that IBD is also changing in
Africa and Latin America. That shows that the number of people with inflammatory bowel
disease (IBD) has been rising in developing places all over the world. More and more people in
these places are getting inflammatory bowel disease (IBD) (Alatab et al., 2020). To help, targeted
interventions and new medical facilities need to be built. This may be because more people live
in cities, eat more Western foods, and get medical care more efficiently.
SCOPING REVIEW 19
People with Crohn's disease (CD) and ulcerative colitis (UC) have inflammatory bowel
diseases (IBD). These diseases have changed a lot in the last few years. It is becoming more
prevalent in Asia, Latin America, and Africa, where the disease is still growing (Kotze et al.,
2020). In the past, it was more common in places like the West. Significant differences exist in
how common and how often people get sick in different parts of the world (Kotze et al., 2020).
This new point of view shows that IBD epidemiology is constantly changing.
People who have inflammatory bowel disease (IBD) have been going to the West for a long time
to get the correct diagnosis and information about their disease. That is because of better
healthcare facilities and diagnostic tools. Some places, like North America and Europe, have a
lot of people who have inflammatory bowel disease (IBD), as shown by Molodecky et al. (2012)
and Kaplan and Ng (2017). Many more people in poor countries are sick, changing how we
study digestive diseases. Studies by Park and Cheon (2021), Hodges and Kelly (2020), and
Saracino et al. (2023) show that this is changing because the rates of occurrence and regularity
are going up in Asia, Africa, and Latin America. Communities in these places are learning about
and getting diagnosed with inflammatory bowel disease (IBD) more because more people are
moving to cities, following Western ways of life, and making healthcare systems better (Kotze et
al., 2020). With more people knowing about inflammatory bowel disease (IBD) and more studies
being done, the problem should be addressed comprehensively. That can be done by improving
healthcare systems around the world.
In Asia, some people are getting inflammatory bowel disease (IBD) more often. Park and
Cheon (2021) found that the reason more people in Asian countries are getting inflammatory
bowel disease (IBD) is that cities are growing quickly, people are moving to urban areas, and
their eating habits are becoming more like those in the West. Studies by Saracino et al. (2023)
SCOPING REVIEW 20
and Hodges and Kelly (2020) show that inflammatory bowel disease (IBD) is becoming more
common in Latin America and Africa. That indicates that the people who live in these places
have changed significantly. More people are moving to cities to get better health care and adopt
Western ways of life, making inflammatory bowel disease (IBD) more widespread in these areas
(Hammer and Langholz 2020). There are more people with inflammatory bowel disease (IBD)
all over the world now due to these social changes. That requires more work on public health,
better healthcare services, and targeted treatments. More people in developing countries are
getting inflammatory bowel disease (IBD) due to a combination of genetic, environmental, and
behavioral factors (Hammer and Langholz, 2020). Some external factors that make inflammatory
bowel disease (IBD) more common are changes in hygiene habits, exposure to pollutants
outside, and food choices. Genetic predisposition is also significant.
It is also challenging to get good health care in places that are not well-developed,
increasing the cases of inflammatory bowel disease (IBD). Healthcare inequality and delays in
diagnosis make it harder to treat illnesses and have better results for patients, as found by
Coward et al. (2019) and Vernon-Roberts et al. (2023). Researchers in these places have found
that people with inflammatory bowel disease (IBD) have more problems because of poor
healthcare systems and inadequate specialized hospitals. Sick people in poor countries often
have problems, like having to wait a long time for doctor visits, lacking diagnostic tests right
away, and medicines and other treatments running out (Guo et al., 2023). Others have a more
challenging time getting the care they need and having good results because they are poor, lack
health insurance, or live far away from other people. It is time to improve healthcare by making
it easier for people to get specialized services and better training healthcare workers (Guo et al.,
SCOPING REVIEW 21
2023). Healthcare professionals should consider creative ways, like telemedicine, to help people
with inflammatory bowel disease (IBD) get the care they need in places without many options.
Public health measures, better access to health care, and a focused study to find out
what's causing the changing epidemiological landscape are factors to consider to even out the
places where inflammatory bowel disease (IBD) is more common. Many people have discussed
the importance of understanding the trends and causes of inflammatory bowel disease (IBD) so
that each area can devise plans for stopping, diagnosing, and treating the disease (Cury et al.,
2019; Yeshi et al., 2020; Bus and Kelly, 2020). Inflammatory bowel disease (IBD) risk factors
should be made more known, and screening programs should be set up so that IBD can be
detected and treated early. These should be the primary goals of public health activities; the
healthcare system needs to be stronger, have more specialized care centers, and have more cheap
and easy-to-get medicines and treatments (Bus and Kelly, 2020). To find new ways to treat
inflammatory bowel disease (IBD) and learn more about how genetic, environmental, and
lifestyle factors work together to make the disease more common, focusing study efforts in this
area is essential (Yeshi et al., 2020). Politicians, doctors, experts, and public health officials need
to share their ideas and work together to improve the lives of people with inflammatory bowel
disease (IBD) worldwide.
All over the world, more and more people are getting inflammatory bowel disease (IBD);
genes, environment, and behavior are the main contributing factors. Truta et al. (2023) and Cui
and Yuan (2018) examined the role of susceptibility genes in the pathophysiology of
inflammatory bowel disease (IBD). Their results highlight the importance of genes.
Environmental factors mainly cause this trend. The number of people with inflammatory bowel
disease (IBD) is likely going up because of changes in hygiene, diet, and exposure to pollution.
SCOPING REVIEW 22
An article from Narula et al. (2021) discusses how eating ultra-processed foods can increase the
risk of inflammatory bowel disease (IBD). Another Buie et al. (2023) article discusses how
outside causes can cause IBD. It is essential to have ways to prevent and treat illnesses that
consider all these things because these data show that genes and the environment can affect how
inflammatory bowel disease (IBD) spreads.
Developing and developed countries significantly differ regarding how quickly people
can get medical care, how they are treated, and how quickly they can get to healthcare facilities.
It is harder to deal with inflammatory bowel diseases (IBD) because of these changes. Verne-
Roberts et al. (2023) and Coward et al. (2019) discuss how these differences significantly affect
patient care and the effectiveness of treatments. In places that do not have many resources,
people with inflammatory bowel disease (IBD) have extra problems, like not getting certain
medicines, a slow healthcare system, and high healthcare prices (Guo et al., 2023). Diseases get
worse faster, and issues are more likely to happen when diagnoses are delayed; different ways of
treating diseases are made worse by differences in their management and their future
effectiveness (Verne-Roberts et al., 2023; Coward et al., 2019). Healthcare workers' availability,
cost, and skill level cause these differences. Regarding healthcare, doctors should make it easier
to identify problems, improve healthcare facilities, and use evidence-based treatment methods
based on the needs of different groups of people (Guo et al., 2023). These variances should be
addressed so that everyone with inflammatory bowel disease (IBD) can get the same high-quality
care.
There are notable differences between developed and developing countries regarding
access to health care, which is essential in treating inflammatory bowel disease (IBD).
Industrialized countries already have excellent healthcare systems (Hammer and Langholz,
SCOPING REVIEW 23
2020). Still, they are even better now that they have centers for inflammatory bowel disease
(IBD), advanced diagnosis and treatment tools, and care teams of people from different fields.
On the other hand, many developing countries have big problems because they lack sufficient
money for IBD services, enough skilled healthcare workers, or adequate healthcare
infrastructure. Hammer and Langholz (2020) and Rajbhandari et al. (2020) discovered that
access to health care is not the same everywhere. There are also specific steps that need to be
taken to make it easier for people in struggling areas to get good treatment. Work together to
make estimates more accurate, train healthcare workers better, and ensure that resources are used
to meet the needs of people in poor countries (Rajbhandari et al., 2020). The goal is to improve
people's health worldwide with inflammatory bowel disease (IBD) and make it easier for them to
get high-quality care.
Delayed IBD diagnoses are a big problem, especially in places with limited medical
resources. Consequently, it is harder to treat the illness quickly and effectively. People with IBD
may have worse clinical outcomes, be more likely to develop complications, and have worse
disease activity due to delayed diagnosis and treatment (Jayasooriya et al., 2023). Several things
can delay a diagnostic test. For instance, it is hard to get diagnostic tests like endoscopy and
imaging studies, and doctors do not know much about the signs of inflammatory bowel disease
(IBD). Additionally, it is challenging for people to get expert gastroenterological services.
Rajbhandari et al. (2020) and Jayasooriya et al. (2023) examined how diagnosis delays affect
disease progression. These studies revealed the significance of early detection and treatment in
improving patients' chances of a good outcome. Healthcare organizations should train healthcare
workers, improve healthcare infrastructure, and make it easy for people to get diagnostic tests to
address diagnostic delays (Rajbhandari et al., 2020). Healthcare systems could speed up
SCOPING REVIEW 24
diagnosis times and improve outcomes for people with inflammatory bowel disease (IBD) by
solving these systemic flaws and encouraging a culture of proactive disease tracking.
How well people with inflammatory bowel disease (IBD) are cared for differs in
developed and less developed countries. One reason for this is that doctors use different kinds of
treatment (Wang et al., 2023). There are set rules for how to treat inflammatory bowel disease
(IBD), but not all healthcare systems offer or can afford the medicines, surgeries, and supportive
therapy that can help people with IBD. People in industrialized places can get biological agents,
immunomodulatory drugs, and certain surgeries (Wang et al., 2023). Some people who live in
areas with limited resources cannot use or pay for these choices. Researchers Coward et al.
(2019) and Hammer and Langholz (2020) found that people with inflammatory bowel disease
(IBD) get and use medicines in various ways. That implies that more resources and help should
be given to everyone with IBD so that they can get the best care (Wang et al., 2023). To eliminate
differences in treatment, healthcare organizations should build better hospitals, train healthcare
workers better, and find cheap ways to get life-saving treatments to places that do not have them.
Moreover, stakeholders need to work together and push for laws that support healthcare
equality to close the treatment gap and make sure that people with the same disease have the
same outcomes everywhere in the world. Coward et al. (2019) and Hammer and Langholz (2020)
proposed there should be a comprehensive plan to address the unfair healthcare for people with
inflammatory bowel disease (IBD). This plan should include several legislative actions,
improvements to healthcare centers, staff training, and community involvement programs
(Coward et al. (2019, Hammer and Langholz, 2020). Governments should build specialized IBD
centers with complete diagnosis and treatment facilities to make it easy for people to get medical
care. Additionally, healthcare organizations should create training programs for people who work
SCOPING REVIEW 25
in healthcare to help them better handle IBD (Coward et al. 2019; Hammer and Langholz, 2020).
Poor or far away communities can get medical care through telemedicine projects, making it
easier for people to keep their meetings and follow-ups. Healthcare workers must learn more
about the signs and symptoms of IBD and use standard diagnostic methods to ensure the correct
diagnosis is made on time (Chen et al., 2023). That will help get rid of diagnostic delays.
Spending money on diagnostic centers and tools is essential to get the job done faster, especially
when money is limited. Making treatments easier to get and cheaper, such as by negotiating drug
prices, pushing for generic drugs, and setting up patient aid programs, can also help lower
financial barriers and ensure everyone with IBD has the same chance to get the therapies they
need (Chen et al., 2023). By combining these steps and getting partners at the local, national, and
global levels to work together, healthcare organizations can do much to improve healthcare for
people with IBD worldwide and close the gaps in care.
Environmental Factors: The risk of getting inflammatory bowel disease (IBD) and its severity
can also be affected by smoking, physical movements, and stress levels. Greuter et al. (2020) and
Lautenschlager et al. (2023) studied how inflammatory bowel disease (IBD) is linked to gender
and lifestyle factors. Their results highlight how these two things cause and spread the disease.
Disease results are also different in developing and developed areas because of differences in
how easy it is to get medical care and how good it is. According to Vernon-Roberts et al. (2023)
and Coward et al. (2019), the unfair healthcare system and long wait times for evaluations that
people with few resources have to deal with make inflammatory bowel disease (IBD) worse in
these groups. Collaborative approaches are necessary to establish IBD’s causes and how to make
it less harmful to public health. Healthcare providers need a complete plan to improve public
health, make it easier for people to get to healthcare services, and study why the burden of IBD
SCOPING REVIEW 26
varies by area to solve this problem. Buie et al. (2023) and Ye et al. (2015) stated that for the
world to make plans to stop inflammatory bowel disease (IBD), find it early, and treat it, people
should fully understand the disease's trends and causes.
Several environmental factors can affect an inflammatory bowel disease (IBD), like
Crohn's disease or ulcerative colitis. Changing how clean you are, what you eat, and how much
you eat ultra-processed foods are all environmental risk factors, making inflammatory bowel
disease (IBD) more popular worldwide. Studies by Narula et al. (2021) and Buie et al. (2023)
shed light on these external factors' role in how diseases spread and grow. A study by Narula et
al. (2021) shows that eating ultra-processed foods can make a person more likely to get
inflammatory bowel disease (IBD). That is a significant link in the development of illness. Buie
et al. (2023) state that people must change things in their surroundings that can make
inflammatory bowel disease (IBD) less severe. They also say that environmental risk factors
make the sickness worse. Accordingly, inflammatory bowel disease (IBD) should not spread
around the world. That implies public health measures should be used to promote healthier lives
and lower exposure to environmental triggers (Jayasooriya et al., 2023). The results show a
strong connection between outdoor exposure and the chance of getting a disease.
Microbiological pathogens are less likely to spread because people have significantly
changed how they clean in the last few decades. Cities are increasing in emerging countries,
which is a significant factor (Jayasooriya et al., 2023). These changes may also have an effect on
the bacteria in the gut, which could make people more likely to get inflammatory bowel disease
(IBD). Hodges and Kelly (2020) and Park and Cheon (2021) found that the rise in inflammatory
bowel disease (IBD) in Africa and Asia is tied to changes in how people clean themselves. These
findings show that changes in the touch between microbes may impact the growth of
SCOPING REVIEW 27
inflammatory bowel disease (IBD). There is also a link between gut health and clean
environments. Jayasooriya et al. (2023) showed that keeping the gut cleaner can lower the
number of germs living there. That might upset the balance of good and bad bacteria and make
the intestines more inflamed, a sign of inflammatory bowel disease (IBD) (Jayasooriya et al.,
2023). It is essential for groups that are moving to cities quickly to understand these changes so
that personalized medicines can be made to support gut health and stop the rising number of
people with inflammatory bowel disease (IBD).
Gut health and the chance of getting inflammatory bowel disease (IBD) are both affected
by the way people eat, which is shaped by culture, society, and the world. IBD is more likely to
happen to people who eat Western-style diets that are high in processed foods, sugary sugars, and
saturated fats. However, traditional diets are full of fiber and are suitable for many foods.
Researchers Narula et al. (2021) and Glassner et al. (2020) have found that what people eat is a
big part of both avoiding and treating inflammatory bowel disease (IBD). People with
inflammatory bowel disease (IBD) can also improve their health by changing their food, such as
following a low-FODMAP (fermentable oligosaccharide, disaccharide, monosaccharide, and
polyol) diet (Narula et al., 2021). These results show the importance of changing diet to deal with
IBD. They show that making some changes to the way people eat might help people with IBD
feel better and lessen the effects of their disease (Glassner et al., 2020). That is why people with
inflammatory bowel disease (IBD) need to get help making and sticking to a healthy diet as part
of their care plan.
People today often eat ultra-processed foods, which have a lot of added chemicals,
stabilizers, and chemicals. IBD is more common in people who eat these foods, and they are
awful for gut health. Digestive problems may be more likely to happen if people eat these things.
SCOPING REVIEW 28
They change the bacteria in the gut, make the intestines swell, and weaken the barrier between
the gut and the outside world (Agrawal et al., 2021). Research by Narula et al. (2021) and Buie et
al. (2023) found that eating highly processed foods is bad for gut health and makes a person
more likely to get inflammatory bowel disease (IBD). Thus, people need to change their food
immediately to eat less of these bad things; they should avoid ultra-processed foods and eat
whole, raw foods high in fiber, vitamins, and minerals (Narula et al., 2021). That will help their
gut health and make inflammatory bowel disease (IBD) less likely. How people eat these days is
making inflammatory bowel disease (IBD) more common. It is helpful for public health
campaigns to teach people about the dangers of eating highly processed foods and to push for
rules that make it easier for people to get healthier food.
A person is likelier to get inflammatory bowel disease (IBD) if they come into contact
with chemicals like bisphenol A (BPA), phthalates, and pesticides. Studies by Narula et al.
(2021) and Glassner et al. (2020) show that to lower the chance of inflammatory bowel disease
(IBD), it is essential to stay away from things that can stress a person out in your environment.
There is a link between exposure to toxins in the surroundings and inflammation in the intestines.
The gut flora changes because of environmental toxins, and the intestinal barrier also does not
work (Agrawal et al., 2021). They also worsen inflammatory reactions and IBD symptoms.
Some factors like smoking, not exercising enough, and worrying can increase the likelihood of
developing inflammatory bowel disease (IBD) (Glassner et al., 2020). That shows the
complicated link between lifestyle and environmental factors that lead to IBD. Some things that
make people more likely to get inflammatory bowel disease (IBD) are smoking and having a
family history of the disease (Narula et al., 2021). On the other hand, being busy and stress-free
can lessen the effects of chemicals and pollutants in the surroundings that cause inflammation
SCOPING REVIEW 29
(Narula et al., 2021). Consequently, the best ways to improve digestive health and lower the risk
of inflammatory bowel disease (IBD) are to live a healthy life and limit exposure to
environmental pollution.
The risk and signs of inflammatory bowel disease (IBD) depend on the individual’s daily
choices. Some things that stand out are whether or not a person smokes, how busy they are, and
how they handle stress (Hammer and Langholz, 2020). People who smoke get a lot of attention
because of the unique ways it affects people with ulcerative colitis (UC) and chronic diarrhea
(CD). Many new things have been learned about how smoking changes the signs and symptoms
of inflammatory bowel disease (IBD) and how the disease responds to treatment. Lautenschlager
et al. (2023) and Greuter et al. (2020) state that smoking increases the chance of getting chronic
diarrhea (CD) and worsens it. However, smoking does not cause ulcerative colitis (UC). The
numbers show that programs that help people quit smoking are a big part of the plan to treat
inflammatory bowel disease. (Hammer and Langholz, 2020) Regular exercise and lowering
stress can change how the body responds to inflammation, the types of bacteria in the gut, and
how well the immune system works. These things can all change how inflammatory bowel
disease (IBD) gets worse (Greuter et al., 2020). If a person with IBD wants to handle their
disease better and stay healthy, they should make lifestyle changes. Some of these changes are
getting more exercise and learning to handle stress better.
Several studies show that exercise can help people with inflammatory bowel disease
(IBD) take charge of their condition. Exercise is also essential for gut health and to change how
the immune system works. Greuter et al. (2020) and Lautenschlager et al. (2023) show exercise
can help people with inflammatory bowel disease (IBD) by making their disease better and
reducing inflammation. These effects come from changing immune responses, lowering
SCOPING REVIEW 30
inflammation, and making the microbiota in the gut more diverse (Lautenschlager et al., 2023).
Adding exercise to the care plan of someone with inflammatory bowel disease (IBD) can help
them get better care that addresses all of their symptoms. Additionally, getting people with
inflammatory bowel disease (IBD) to exercise can help them improve their health and make
them less likely to have flare-ups or other problems (Hammer and Langholz, 2020). To help
patients with IBD get the best results and have a better outlook in the long run, it is essential to
include exercise in their care.
Genetic Predisposition: Some genetic and social factors make people more likely to get
inflammatory bowel disease (IBD) and make it worse. Several genetic and environmental factors
interact complexly to cause inflammatory bowel disease (IBD) (Greuter et al., 2020). These
factors are changed by gender, choices like smoking, not exercising, and stress management.
Greuter et al. (2020) and Lautenschlager et al. (2023) describe how these things can increase the
risk of getting inflammatory bowel disease (IBD) and its severity. Individuals with inflammatory
bowel disease (IBD) are different in how the disease makes them feel (Greuter et al., (2020).
That shows that people are more or less likely to get the disease depending on their genes,
hormones, and culture. IBD is passed down through some genes. DNA differences can change
how likely someone is to get IBD and how it looks (Lautenschlager et al., 2023). Both genome-
wide association studies and family grouping prove this. Some habits, like smoking, working
out, and how people handle stress, increase the risk of developing inflammatory bowel disease
(IBD) (Mak et al., 2023). These habits can affect the immune system, the microbiota in the gut,
and the health of the intestinal barrier. Professional healthcare providers should learn more about
how genetic and lifestyle factors affect each other to develop more effective ways to avoid and
treat inflammatory bowel disease (IBD) and to understand how it develops.
SCOPING REVIEW 31
People with inflammatory bowel disease (IBD) have very different rates of getting it,
having bad symptoms, and responding well to treatment. That highlights the importance of
differences between men and women in the disease's numbers and manifestation (Mak et al.,
2023). According to Greuter et al. (2020), the type of disease and how quickly it spreads are
different for men and women. Regarding perianal disease and signs outside of the intestines,
women are more likely than men to have them. Additionally, their sicknesses tend to get worse
faster. Because of these differences, men and women with inflammatory bowel disease (IBD)
should be treated and managed in different ways (Mak et al., 2023). Men and women may be
more or less likely to get sick, have different immune systems, and have different types of
bacteria living in their guts. These differences could be due to changes in hormones, genes, and
society. People with inflammatory bowel disease (IBD) should know about these changes
between men and women to maximize their treatment and have the fewest side effects (Buie et
al., 2023). These issues should be addressed in clinical practice, but first, healthcare providers
must learn more about why men and women with inflammatory bowel disease (IBD) are
different and how to fix them (Buie et al., 2023). If healthcare professionals thought about the
needs of both male and female patients, they might treat inflammatory bowel disease (IBD)
better and get more positive results for their patients.
Genome-wide association studies (GWAS) have different areas that are more likely to get
the condition. Genetics can make a person more likely to get inflammatory bowel disease (IBD).
Inflammatory bowel disease (IBD) is primarily caused by genetic changes in how the immune
system works, how the barrier works, and how microbes interact. Truta et al. (2023) and Cui and
Yuan (2018) showed that genetics are a big part of how likely someone is to get inflammatory
bowel disease (IBD). That shows the significance of using individual treatment plans based on
SCOPING REVIEW 32
each person's genetic information. It is essential to consider genetic diversity when developing
new ways to treat inflammatory bowel disease (IBD) (Truta et al., 2023). By examining the
genetic causes of inflammatory bowel disease (IBD), healthcare professionals can identify new
targets for therapy and make more effective precision medicine treatments (Cui and Yuan, 2018).
Doctors can better care for people with inflammatory bowel diseases by using DNA information
to determine how likely they are to get a disease and make personalized treatment plans.
Psychosocial Impacts of IBD: Some new research shows that both mental and physical stress
can worsen inflammatory bowel disease (IBD). People who are stressed out may be more likely
to get inflammatory bowel disease (IBD) or have it worse (Guo et al., 2023). That is because
stress changes the bacteria in the gut, makes the gut barrier weaker, and has many other effects
on the immune system. Studies by Greuter et al. (2020) and Lautenschlager et al. (2023) have
shown the importance of learning how to deal with stress to stay healthy and improve. They have
shown that there is a complicated link between worry and the chance of getting inflammatory
bowel disease (IBD) (Greuter et al., 2020; Lautenschlager et al., 2023). Cognitive-behavioral
therapies and mindfulness-based therapies may help lower the effects of stress on the results of
inflammatory bowel disease (IBD) by making people feel better emotionally and giving them
better coping skills and mental toughness (Guo et al., 2023). By including methods for dealing
with stress in complete IBD care plans, doctors show they are entirely treating the disease,
considering the physical and mental parts of it (Greuter et al., 2020; Lautenschlager et al., 2023).
Doctors can help people with inflammatory bowel disease (IBD) control their symptoms and
improve their quality of life by teaching them healthy ways to deal with stress.
Ni et al. (2024) and Alatab et al. (2020) show that fistulas also significantly affect quality
of life because they can lead to repeated infections and fecal leakage. To solve these problems,
SCOPING REVIEW 33
the review stresses the importance of comprehensive care. This aligns with studies by Ni et al.
(2024) and Abegunde et al. (2016) that support personalized management methods that lead to
better patient outcomes. Kaplan and Windsor (2021) and Vedamurthy and Ananthakrishnan
(2019) say this needs a multidisciplinary approach combining drug therapies and surgical
methods. Kaplan and Windsor (2021) also noted that finding and treating extraintestinal
symptoms as soon as possible is essential for preventing long-term problems and making patients
happier. By putting together evidence from many different sources, the study shows how
important it is to use comprehensive management methods to deal with the complicated
complications of IBD and improve patient care.
Researchers who study the quality of life (QoL) of people with inflammatory bowel
disease (IBD) have found that the disease has a significant effect on many aspects of the patient's
life. Quality of life (QoL) in people with IBD comprises physical, mental, and social factors.
Researchers Molodecky et al. (2012) and Kaplan and Ng (2017) discussed this in more detail,
showing that the action of a disease, which includes flare-ups and remissions, significantly
affects a person's quality of life. During active illness stages, people have more symptoms and
cannot do as much. Alatab et al. (2020) also discuss how therapeutic side effects can hurt
patients' quality of life. Medicines can cause these side effects, including nausea, tiredness, and
infusion responses.
According to studies by Greuter et al. (2020) and Vernon-Roberts et al. (2023),
psychosocial factors significantly affect the quality of life (QoL) of people with inflammatory
bowel disease (IBD). Psychosocial problems like depression, anxiety, and social stigma
significantly impact how well people can handle their emotions and social interactions. It is
common for people with IBD to feel lonely, ashamed, and unsure about the future, all of which
SCOPING REVIEW 34
lower their quality of life (Vedamurthy and Ananthakrishnan, 2019). Additionally, the shame that
comes with having IBD symptoms like stomach pain and fecal incontinence can make patients'
mental health worse by making them withdraw from society and have worse relationships with
others (Vedamurthy and Ananthakrishnan, 2019). These psychosocial effects highlight the
importance of treating IBD's emotional and social problems along with its physical ones. By
providing comprehensive support that addresses patients' psychological needs, healthcare
professionals can enhance their patients' general quality of life and make them more resilient in
dealing with the difficulties of inflammatory bowel disease (IBD).
Some studies explored juvenile inflammatory bowel disease (IBD), showing how this age
group of patients has unique symptoms, makes it harder to diagnose, and needs different
treatment ways. Molodecky et al. (2012) and Kaplan and Ng (2017) said that early-onset IBD
should be seen as a different type of disease with its unique symptoms and course. Compared to
adults, young patients often show more aggressive disease behavior, a more comprehensive
range of disease involvement, and a higher rate of perianal participation at presentation. Alatab et
al. (2020) discussed how hard it is to find juvenile IBD because signs like diarrhea, weight loss,
and abdominal pain can happen at the same time as common childhood illnesses. That makes
diagnosis take longer, and the condition is not detected as much as it should be.
Regarding kids and teens, inflammatory bowel disease (IBD) makes it hard for them to
grow, develop, and fit in with their peers. They need specialized therapy tailored to their specific
needs. Vernon-Roberts et al. (2023) and Greuter et al. (2020) did studies showing how IBD
significantly affects children's eating and physical growth. Side effects of treatment and ongoing
disease can make growth retardation worse, delay puberty, and hurt bone health. The problems
that pediatric patients and their families face are worsened by psychological factors such as
SCOPING REVIEW 35
mental pain, social stigma, and missing school (Greuter et al., 2020). These parts stress the
importance of using all-around treatment plans that include more than just managing the
sickness. These should consist of things like psychosocial support and educational programs.
Pediatric IBD centers with multidisciplinary teams of pediatric gastroenterologists, dietitians,
psychologists, and social workers are the best places to take care of the complex needs of young
patients (Vernon-Roberts et al., 2023). Healthcare workers can improve the overall health of kids
with IBD and their families by treating the disease in a way that considers its physical,
emotional, and social implications. That will help improve the patient’s results.
The long-term effects of inflammatory bowel disease (IBD) in children are still being
studied. Vernon-Roberts et al. (2023) and Greuter et al. (2020) have shown this group's wide
range of disease courses and results. Longitudinal studies are needed to get a better
understanding of the natural history of juvenile IBD. These studies should examine how the
illness worsens, its response to treatment, and the chance of problems like not growing correctly
structuring disease, and colon cancer. By observing the long-term paths of children with IBD,
researchers can learn more about the factors that affect how the illness progresses and make
changes to treatments (Vernon-Roberts et al., 2023). It is essential to find pediatric patients who
are at high risk quickly. That lets personalized treatment plans be implemented to slow the
disease's progression and improve long-term outcomes through risk assessment and close
tracking. Additionally, kids and teens with IBD need to be constantly monitored and get follow-
up care to see how their treatment is going, deal with any new problems that come up and
improve their overall health and well-being (Vernon-Roberts et al., 2023; Greuter et al., 2020).
Researchers, healthcare professionals, and patient advocacy groups can work together to improve
SCOPING REVIEW 36
IBD treatment and study for kids. That will help patients do better and make life better for those
who are affected.
Healthcare Costs: The scoping review reveals that inflammatory bowel disease (IBD) costs
society a lot of money. This burden comes in many forms, such as direct medical costs, indirect
costs related to lost output and disability, and intangible costs related to a lower standard of
living (Molodecky et al., 2012). The rising number of people with IBD and more people using
healthcare services, along with the increasing cost of specialized treatments like biologic
therapies and surgery, have contributed to the rising costs of managing IBD. Molodecky et al.
(2012) and Kaplan and Ng (2017) also noted that these direct healthcare costs are high and strain
people and healthcare systems. They include hospital stays, outpatient visits, prescription drugs,
diagnostic tests, and surgeries.
With inflammatory bowel disease (IBD), there are also indirect costs like lost output,
missing work or school, and expenses related to disability. Saracino et al. (2023) and Alatab et al.
(2020) studies show that IBD significantly affects patients, their families, and society. People
with IBD often have trouble keeping a job, going to school, and taking care of their social
obligations because their sickness and its symptoms are so debilitating (Alatab et al., 2020). IBD
flare-ups are also hard to plan for, and people with it have to go to the doctor and stay in the
hospital a lot. That makes it more likely that they will miss work or school, costing more for the
affected people and their families, the healthcare system, and everyone else (Saracino et al.,
2023). The sum of these indirect costs highlights the significance of having comprehensive
support networks that include social services, disability payments, and job modifications to
lessen the adverse effects of IBD on people's finances and improve their quality of life (Saracino
SCOPING REVIEW 37
et al., 2023; Alatab et al., 2020). The cost of IBD can also be lowered by working to make it
easier to control and lessen its symptoms through early diagnosis and effective treatment plans.
People with inflammatory bowel disease (IBD) often do not think about the hidden costs
of the disease, like worsening health, mental pain, and a poor quality of life. Mood, physical, and
social health can all be affected by inflammatory bowel disease (IBD). Narula et al. (2021) and
Buie et al. (2023) discuss this; likely, symptoms like stomach pain, diarrhea, being tired, and
needing to go to the bathroom a lot are linked to destructive emotions like anger, loneliness, and
needing help from other people. It is hard on people's mental health and quality of life to have a
chronic disease and worry about how it will get worse, the side effects of treatment, and being
judged by others (Waqar et al., 2023). People with inflammatory bowel disease (IBD) have to
deal with constant mental stress, flare-ups that are hard to predict, and the need to be cared for
and tracked all the time. When these things happen, they feel more or less in charge, good about
themselves, or optimistic about the future (Waqar et al., 2023). Individuals with inflammatory
bowel disease (IBD) need patient education, psychosocial assistance, and ways to improve their
emotional health, resilience, and ability to cope to deal with these hidden costs.
Their financial status affects patients' overall quality of life (QoL), making it harder for
them to get medical help, alternative treatments, and support services. Coward et al. (2019) and
Hammer and Langholz (2020) discovered that healthcare access and cost differ for everyone.
These differences cause variance in how the disease is treated and how well it works, which
worsens inflammatory bowel disease (IBD) in patients' quality of life. People from
disadvantaged or marginalized groups often have more problems getting good care, like not
having enough money, having no health insurance, or living far away from healthcare facilities
(Coward et al., 2019). Thus, these patients may not have enough access to multidisciplinary care,
SCOPING REVIEW 38
may not follow through with their treatment, and may have to wait too long for a diagnosis.
These factors can make it harder for them to handle their condition and hurt their overall health
Langholz (2020). A patient's access to mental health services, ability to follow dietary guidelines,
and ability to pay for drugs are all affected by their socioeconomic status, which lowers their
quality of life. To improve the quality of life for people with IBD, healthcare providers must
address the problems that make it harder for some people to get healthcare or make it too
expensive for others (Coward et al., 2019; Hammer and Langholz, 2020). That calls for tactics
that ensure all patients have equal access to high-quality care and supportive services, no matter
how much money they have.
The information in this scoping review explains in-depth the psychological and social
aspects of inflammatory bowel disease (IBD). For instance, it shows how people with IBD deal
with their condition, their social networks, and how likely they are to stick to their treatment
plans. Kaplan and Ng (2017) and Glassner et al. (2020) have shown that inflammatory bowel
disease (IBD) and mental health are connected in a complex way. They found that people with
IBD are more likely to be depressed and anxious and have a lower quality of life. People who
have had Irregular bowel disease (IBD) for a long time can find it very upsetting because their
symptoms change all the time, and treatment is not always successful (Kaplan and Ng, 2017).
People with inflammatory bowel disease (IBD) may already feel more shame, loneliness, and
social withdrawal because of the bad feelings that come with having bowel symptoms like leaky
stools and frequent trips to the bathroom (Glassner et al., 2020). Consequently, it is essential to
deal with the social and mental aspects of inflammatory bowel disease (IBD) (Kaplan, 2022).
Healthcare providers should use various care methods, such as psychological support, coping
techniques, and education, to help patients be stronger, stay in treatment, and be healthier overall.
SCOPING REVIEW 39
There are various ways that people with inflammatory bowel disease (IBD) deal with the
physical and mental effects of their condition. According to Hodges and Kelly (2020) and
Saracino et al. (2023), some of these are learning how to deal with problems, getting help from
others, relaxing, and adding complementary treatments to daily plans. Effective coping makes
people mentally stronger and more flexible and lets them take part in managing their sickness
and making decisions about it (Hodges and Kelly, 2020). To lessen the adverse effects of
inflammatory bowel disease (IBD) on mental health and improve overall health, it is also
essential to have strong social support networks with family, friends, healthcare workers, and
patient advocacy groups.
People with inflammatory bowel disease (IBD) are more likely to take their medicines and use
healthcare services when they are feeling good. That is an essential part of controlling the
disease.
Several factors, such as beliefs about medications, how well treatments are thought to
work, social support, and the provision of healthcare services, play a role in how well people
with inflammatory bowel disease (IBD) stick with their treatments (Coward et al., 2019; Vernon-
Roberts et al., 2022). To eliminate psychosocial barriers that keep people from sticking with their
treatment, healthcare providers need a comprehensive plan that includes educating patients,
helping them communicate, giving them psychological support tools, and letting patients and
healthcare workers make decisions together. There is a better chance for people with
inflammatory bowel disease (IBD) and their families if their doctors know about and meet their
mental, social, and emotional needs (Hodges and Kelly, 2020). That will also help with care and
living a better life. Doctors must realize that teaching and giving people power are essential for
helping them become more resilient and learn how to care for themselves.
SCOPING REVIEW 40
People need to get complete and correct information about their illness, treatment
options, and changes to their lifestyle. Studies by Hodges and Kelly (2020) and Saracino et al.
(2023) show that when someone has inflammatory bowel disease (IBD), they should be taught
about the long-term effects, how to deal with symptoms, and what might happen. That will get
them more involved in their care. Better health literacy and patient-provider decision-making
also help people take their medicine by giving them more details to help them decide what to do
(Saracino et al., 2023). Patients can feel stronger and more in charge of their health thanks to
many websites, support groups, and programs that teach them about their conditions. People with
inflammatory bowel disease (IBD) can feel more confident in their ability to handle their
condition (Saracino et al., 2023). They will more likely adhere to their treatment if given the
necessary knowledge and skills. That can also improve their overall quality of life.
Novel Treatment Approaches: This study explores biological medicines, small compounds, and
new ways to give drugs. As shown in studies by Molodecky et al. (2012) and Kaplan and Ng
(2017), biological drugs can stop the production of pro-inflammatory cytokines and immune
pathways that worsen inflammatory bowel disease (IBD). They showed that biological drugs like
vedolizumab, ustekinumab, and anti-tumor necrosis factor (TNF) antibodies can help people get
and stay in clinical remission, avoid many hospital stays and surgeries, and have a better quality
of life (Molodecky et al., 2012; Kaplan and Ng, 2017). Moreover, people with inflammatory
bowel disease (IBD) may get better care for less money now that generic medicines have been
made.
Studies reveal that with biological drugs, small molecules are becoming increasingly
crucial for treating inflammatory bowel disease (IBD). There are small chemicals known as
Janus kinase (JAK) inhibitors and sphingosine-1-phosphate receptor modulators that stop
SCOPING REVIEW 41
signaling pathways that make the intestines swell (Desai and Dhoble, 2024). They can be used
instead of biological medicines for people who do not respond to or cannot handle them. Small
chemicals might be helpful because they are easy to take by mouth, work quickly, and can target
intracellular signaling pathways that play a role in inflammatory bowel disease (IBD)
pathophysiology, according to Alatab et al. (2020) and Saracino et al. (2023). Small molecules
might be better than biological treatments in terms of their cost, ease of use, and how much they
make the immune system react. They may also give patients more therapy options and help them
adhere to their treatment and get better results (Alatab et al., 2020; Saracino et al., 2023). More
research is necessary to fully understand how small molecules might work when combined with
biologics or traditional immunosuppressant drugs. Healthcare providers must also know how
safe, effective, and best to use them to treat inflammatory bowel disease (IBD) in the long run
(Desai and Dhoble, 2024). Additionally, scientists are developing new ways to deliver drugs so
that small-molecule treatments can reach more cells and work better in certain places.
Drugs for people with inflammatory bowel disease (IBD) might work better, be safer, and
be more accessible for patients to use if scientists can find new ways to get them to those
patients. New treatments like biodegradable implants, putting therapeutic agents inside
nanoparticles, and sending drugs directly to inflamed gut mucosa are meant to make people more
likely to adhere to their treatments, lower the harmful effects on the whole body, and make it
easier for medicines to get to target cells (Kaplan, 2022). New drug transport methods, like those
examined by Narula et al. (2021) and Buie et al. (2023), may help people with inflammatory
bowel disease (IBD) get better treatment results by getting around the problems that come with
regular drug formulations. TDS can raise drug levels in certain areas while lowering drug
exposure throughout the body and the adverse effects (Buie et al., 2023). They do this by sending
SCOPING REVIEW 42
medicines straight to the inflamed area. Some medications can be put inside nanoparticles to
make their effects last longer and reduce how often they need to be taken (Buie et al., 2023;
Narula et al., 2021). That lets the release rates be managed and enhances the tissue penetrating.
People with biodegradable implants may need to take less time and over a longer time. That
could help them follow through with their care plans (Kaplan, 2022). To better treat
inflammatory bowel disease (IBD), more research needs to be done on how to make these new
ways of giving medicines work better in the clinic.
Along with teaching and giving patients more power, adding psychological treatments to
their ordinary IBD care can help them deal with their symptoms and be stronger. As shown by
Glassner et al. (2020) and Vernon-Roberts et al. (2023), psychosocial treatments like Cognitive
behavioral therapy (CBT), Mindfulness-Based Stress Reduction (MBSR), and Acceptance and
commitment therapy (ACT) can make a big difference in the mental health and quality of life of
people who have been diagnosed with inflammatory bowel disease (IBD) (Glassner et al. 2020;
Vernon-Roberts et al., 2023). These therapies help people learn new ways to handle stress, get
better at living, and become more aware of and open to the problems that come with having a
mental illness (Glassner et al., 2020; Vernon-Roberts et al., 2023). Cognitive behavioral therapy
(CBT) can help people become more aware of and change their negative thinking.
It can also help people with anxiety and sadness get better and teach them better ways to
solve problems. On the other hand, meditation and slow exercise are the basis for Mindfulness-
Based Stress Reduction (MBSR). Its purpose is to help people feel less stressed, accept
themselves without judging them, and be more aware of the present time (Vernon-Roberts et al.,
2023). Acceptance and commitment therapy (ACT) helps people deal with challenging emotions
and thoughts by assisting them to set essential goals, clarify their values, and act in ways that
SCOPING REVIEW 43
align with their beliefs (Glassner et al., 2020; Vernon-Roberts et al., 2023). Adding these
psychosocial treatments to specialized IBD care helps doctors meet their patients' needs, make
them feel better, and give them better ways to handle things (Hodges and Kelly, 2020). These
changes will help people stay healthy and make their treatments work better.
Patients should build solid therapeutic relationships and speak well with their healthcare
professionals. That will help them deal with mental health issues and get the most out of their
treatment. Hodges and Kelly (2020) and Coward et al. (2019) showed that trust, teamwork, and
decision-making are essential for health management. They help customers and providers get
along well. People who are caring and open with each other are more likely to report their
symptoms properly and follow their treatment plan. That also allows them to discuss their
worries, preferences, and treatment goals (Glassner et al., 2020; Vernon-Roberts et al., 2023). In
turn, healthcare experts are vital for calming down patients, helping them deal with their
emotions, and giving them advice tailored to their needs and wants. Building a mindset of
cultural humility and diversity sensitivity is essential to ensure that all patients get fair and kind
care and consider their different racial and cultural beliefs and backgrounds (Coward et al.,
2019). Inflammatory bowel disease (IBD) patients are more likely to be active and happy and
have better outcomes when their care is centered on them. They have therapeutic relationships
based on empathy, mutual respect, and trust.
Discussion and Conclusion
This large study aimed to learn more about the prevalence of inflammatory bowel disease
(IBD), its causes, and changes between developed and developing countries. A literature review
sheds light on the effects of inflammatory bowel disease (IBD) on people worldwide, genetic and
environmental risk factors, healthcare disparities, and what these findings mean for public health
SCOPING REVIEW 44
practice and policy. This analysis also raised several essential topics. IBD affects people
worldwide, no matter where they live, which was an extensive study theme. Changing hygiene
habits, eating habits, and being exposed to ultra-processed foods are some of the external risk
factors identified as significant contributors to the rising number of people with inflammatory
bowel disease (IBD). It took targeted interventions to improve disease outcomes and lower
healthcare delivery inequities caused by differences between developing and developed areas in
healthcare access, diagnostic delays, and treatment methods. These results reveal the importance
of dealing with risk factors that can be changed, encouraging healthy lifestyles, and making it
easier for people to get medical care to lower the number of people with inflammatory bowel
disease (IBD) and improve their health outcomes. These results have significant implications for
public health practice and policy.
Understanding why inflammatory bowel disease (IBD) is becoming more common and
happening more often around the world is crucial. Inflammatory bowel disease (IBD) has been
more common in the West for a long time, but it is becoming more common in developing
countries. That indicates that the epidemiological picture is changing, and we must immediately
pay attention. Public health measures should be used to encourage healthy lifestyles and lower
exposure to risk factors. That is because environmental factors, like changes in food and hygiene
habits, play a significant role in developing diseases. These data reveal why people should
change variables affecting health outcomes to improve global health and lower the growing
burden of inflammatory bowel disease (IBD). To lessen the effects of inflammatory bowel
disease (IBD) on society and improve the health of people who have it, we need to work together
to raise awareness, come up with ways to avoid it, and make healthcare more available to more
people.
SCOPING REVIEW 45
More people are getting inflammatory bowel disease (IBD), which impacts their daily
lives, healthcare services, and the community. People with inflammatory bowel disease face
significant mental, social, and financial problems that make it hard for them to function and
affect their health. Patients and their families have a hard time because it lasts a long time, flares
up at strange times, and is hard to treat. Additionally, healthcare inequality worsens things for
people with inflammatory bowel disease (IBD), especially in developing countries where they
have insufficient specialized treatment choices. It is essential to address these problems to ensure
everyone has equal access to health care and that patients improve. The direct and secondary
costs of inflammatory bowel disease (IBD) on individuals and society, such as medical bills and
lost work time, exemplify the need for cost-effective healthcare policies and disease management
programs.
Several things can cause inflammatory bowel disease (IBD), including genetics, the
surroundings, and unequal access to health care. Genetics and environmental factors such as
hygiene habits and diet can affect the start and progression of inflammatory bowel disease (IBD).
Inequalities in healthcare access, diagnostic delays, and treatment methods exacerbate things for
individuals with inflammatory bowel disease (IBD), especially in places with few resources.
Public health campaigns that promote healthy lifestyles, changes to the healthcare system that
ensure everyone has equal access to high-quality care, and focused studies to explain how
inflammatory bowel disease (IBD) works are essential in addressing these problems. Treating
these factors at the systemic level can lead to a better quality of life and less inflammatory bowel
disease (IBD) pain.
Understanding what causes inflammatory bowel disease (IBD) is essential to improve
public health practice and policy that aims to avoid illness, detect it early, and treat it. Finding
SCOPING REVIEW 46
environmental risk factors, like changes in eating and hygiene habits, highlights the need to
promote healthy living choices and improve access to clean water and nutritious food options.
Likewise, it is crucial to have personalized plans for managing inflammatory bowel disease
(IBD) based on each patient's risk profile. These plans should consider both the person's genes
and their lifestyles. These factors can be changed through targeted public health policies and
measures that will improve the health outcomes and quality of life for people with inflammatory
bowel disease (IBD).
Strengths and Limitations: By carefully reviewing relevant studies from around the world,
scoping reviews are helpful because they give a broad picture of the factors leading to
inflammatory bowel disease (IBD). This review provides a more complete picture of the
epidemiological context and risk factors for inflammatory bowel disease (IBD) by including
research from various settings. This approach makes the data more useful for other groups by
finding more patterns and trends affecting many people. The study's results are also more reliable
because the organized review process ensures that data selection and analysis are open and
thorough.
However, the study has some notable limitations. First, publication bias could have
skewed the results. Studies that find a statistically significant outcome are more likely to be
published than those with no or negative outcome. Due to this bias, we might overstate how
common and essential some risk factors for inflammatory bowel disease (IBD) are. Additionally,
it might be hard to draw firm conclusions from the review results because the studies used
different sample sizes, designs, and methods to measure outcomes, which causes heterogeneity.
The review may not have been as thorough as it could have been because crucial research was
accidentally left out because of the inclusion and exclusion criteria used. Despite these
SCOPING REVIEW 47
shortcomings, the scoping review excellently reveals what inflammatory bowel disease (IBD) is
and its development.
Recommendations for Future Research: For future research on inflammatory bowel disease
(IBD), longitudinal studies should be used to find new risk factors and monitor how they change
over time. Longitudinal study methods are helpful for following changes in the number of cases,
the population of people with it, and the factors that affect those cases to understand how
inflammatory bowel disease (IBD) spreads and changes over time. By monitoring patients for a
long time, we can learn more about the disease's natural course, the early warning signs of its
growth, and how environmental and lifestyle factors affect long-term outcomes. Comparative
studies of illness factors between people in developing countries and the Western world are
essential in determining what is causing the changes in the incidence of inflammatory bowel
disease (IBD). These studies can help make more targeted plans to close the gap by showing
differences between regions regarding the number of illnesses, risk factors, and access to health
care.
In the future, researchers should also examine how well healthcare policy and public
health programs help lessen the effects of inflammatory bowel disease. Interventional studies
investigating how healthcare access, hygiene promotion, and nutrition treatments affect the
number of diseases and their results help shape policy and practice. Knowing how well
telemedicine, patient education programs, and joint treatment models work can also help people
with inflammatory bowel disease (IBD) better handle their illness and improve their quality of
life. Future studies can help lessen the effects of inflammatory bowel disease (IBD) on people
around the world and make people who have it healthier by working on these areas.
SCOPING REVIEW 48
Implications for Practice: The findings of this scoping study are vital for clinical practice and
public health policy as researchers determine the best way to treat inflammatory bowel disease
(IBD). Since inflammatory bowel disease (IBD) is challenging, doctors and nurses must learn
about it to treat patients effectively and help them daily. When doctors care for their patients,
they should also examine how their daily lives and places affect and worsen their sickness.
Healthcare workers can help patients get advanced care and live better lives using a patient-
centered method that considers each person's unique needs and situations.
The data reveals that public health actions are vital to reducing the prevalence of
inflammatory bowel disease (IBD). Addressing these changeable factors reduces the disease’s
prevalence and severity. Accordingly, people should be encouraged to live healthy lives,
including better stress management practices, a balanced diet, and frequent physical exercise.
Authorities should set up programs that make it easier for people, especially those who live in
poor areas, to get medical care. That will help ensure that people with inflammatory bowel
disease (IBD) get a correct diagnosis and treatment right away. A goal of public health officials
who want to improve health and quality of life should be to lessen the effects of inflammatory
bowel disease (IBD) on people and communities. They can achieve this goal by focusing on
equal access to health care and preventative steps.
Conclusion
In conclusion, reviewing several studies on inflammatory bowel disease (IBD) reveals its
complexity and subsequent treatment challenges. In the main body, information from many
academic sources shows the importance of studying inflammatory bowel disease (IBD) to help
patients improve and learn more about the disease. Inflammatory bowel disease (IBD) is
becoming a significant healthcare problem globally. More studies should be done on healthcare
SCOPING REVIEW 49
access and outcomes variations by area, how to make treatments more effective while
minimizing side effects, and how to create personalized therapies. A patient-centered and
multidisciplinary approach is needed to overcome the problematic IBD treatment process and
help people with IBD live better lives.
SCOPING REVIEW 50
SCOPING REVIEW 51
APPENDIX
Appendix 1: Data Form
1. Study Characteristics Form
Author(s)
Year of publication
Study design
Sample size
Disease type
2. Participant Characteristics Form
Disease duration
Demographics (age, gender)
Disease severity
3. Outcome Measures Form
Medical complications (e.g., strictures, fistulas)
Treatment modalities (e.g., biological drugs, small molecules)
Quality of life assessments (e.g., SF-36, IBDQ)
Socioeconomic factors (e.g., income, education)
4. Key findings
Quantitative data
Effect sizes
Statistical significance.
Appendix 2: Sample Article Screening Results (Qualified Articles)
SCOPING REVIEW 52
Study Characteristics Details
Author(s) and Date
Kaplan and Ng (2017); Glassner et al. (2020); Narula et al. (2021); Buie et al. (2023);
Park and Cheon (2021); Hodges and Kelly (2020); Saracino et al. (2023); Coward et
al. (2019); Hammer and Langholz (2020); Vernon-Roberts et al. (2023); Alatab et al.
(2020); Truta et al. (2023); Cui and Yuan (2018); Greuter et al. (2020); Lautenschlager
et al. (2023)
Aim(s) or Research
Questions
Investigate various aspects of IBD epidemiology, risk factors, and determinants across
different geographic regions.
Study Population Patients diagnosed with IBD across diverse demographics and geographical locations.
Mean Age of
Participants Differed across studies.
Gender Male and Female
Percentage of Women Different based on studies
Percentage of Men Varied across studies.
Geographic Setting Included rural and urban settings
Study Design Included retrospective cohort studies, cross-sectional studies, and systematic reviews
Type of Intervention
and Outcomes Differed across studies.
Most Relevant Increase in IBD incidence observed globally, with shifting epidemiological trends.
SCOPING REVIEW 53
Study Characteristics Details
Finding
Most Significant
Finding
Risk factors, treatment modalities, healthcare disparities, and psychosocial factors
impact IBD prevalence.
Study Limitations and
Implications
Limitations include potential biases, limited generalizability, and challenges in data
collection.
Implications include the need for further research, targeted interventions, and
improved healthcare access.
Interpretation and
Conclusions from
Authors
Interpretations and conclusions vary based on study findings, with implications for
healthcare policy, clinical practice, and future research directions.
Appendix 3: Sample of Search Strategy Flow
Identification of Research Question: Inflammatory bowel disease (IBD) is a global health
concern, and this scoping review aims to investigate its prevalence, causes, and regional
variations.
Development of Search Strategy: We adopted a systematic approach to create an all-
encompassing search strategy. Results for inflammatory bowel disease (IBD), epidemiology, risk
factors, and geographical regions were determined using relevant MeSH terms and keywords.
We utilized the Boolean operators (AND, OR) to combine search words effectively.
SCOPING REVIEW 54
Selection of Databases: The literature search uses several electronic databases, such as Web of
Science, Scopus, PubMed, and Embase. These databases provide substantial coverage of the
biomedical literature to guarantee a comprehensive retrieval of pertinent studies.
Execution of Search: The search technique is conducted in chosen databases by employing
suitable syntax and filters to refine the outcomes. Reference management software can then
screen and analyze the search results further.
Screening Process: Before any papers are included in the final screening, their titles and
abstracts are reviewed for relevance to the research issue. Research articles are screened for
relevance and then chosen for full-text review based on whether they fulfill the inclusion criteria.
Full-Text Review: To decide which papers to include in the scoping review, a comprehensive
full-text review is performed on the selected papers. A study's design, population, and outcomes
must all match specific requirements.
Data Extraction: Relevant data are extracted from the included research using a standardized
data extraction form. Crucial details, including the name of the author(s), the year of publication,
the study's methodology, the participants, and the primary results, are documented.
Synthesis of Results: The collected data is combined to find trends, commonalities, and
knowledge gaps in the literature. The study subject is thoroughly examined based on the
findings, which are summarized and presented in a systematic style.
Reporting: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses
Extension for Scoping Reviews (PRISMA-ScR) criteria were followed in reporting the scoping
review's outcomes.
SCOPING REVIEW 55
Appendix 4: PRISMA-ScR Flow Chart
Id
en
ti
fic
ati
on
Studies included in
qualitative synthesis
(n = 30)
Full-text articles excluded,
with reasons
(n = 30)
Full-text articles assessed
for eligibility
(n = 60)
Records excluded
(n = 360)
Records screened
(n = 420)
Records after duplicates removed
(n = 420)
Additional records identified
through other sources
(n = 20)
Eli
gib
ilit
y
In
cl
ud
ed
Sc
re
en
in
g
Records identified through
database searching
(n = 480)
